Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: Gary Korn who wrote (763)	12/16/1999 8:40:00 AM
From: William Partmann	Read Replies (2) \| Respond to of 10345

Elan's Betabloc Enters Clinical Studies for Treatment of Alzheimer's Disease DUBLIN, Ireland, Dec. 16 /PRNewswire/ -- Elan Corporation, plc (NYSE: ELN - news; ''Elan'') today announced that it has initiated Phase I clinical studies with Betabloc (AN 1792), its new therapeutic agent intended for the treatment of Alzheimer's disease (''AD''). In animal studies, published in Nature in July of this year, Betabloc prevented the buildup and reduced the level of established amyloid plaque, considered by many scientists to be one of the main causes of AD. Based on these results, Elan has initiated clinical development to study the potential of this product candidate as a disease modifying agent. The Phase I studies, conducted in patients with moderate AD, are designed to study safety and tolerability of the product candidate following a single administration of the drug. The study, which will include up to 48 patients, will evaluate several dose levels of Betabloc and is expected to take one year to complete. Elan hopes to commence multidose studies in Europe in the spring of next year. ''We are delighted that we have been able to move Betabloc so quickly into the clinic,'' said Donal Geaney, chairman and chief executive officer of Elan. ''The initiation of this study represents an important milestone for Elan's significant research efforts in AD. As far as we know Betabloc is the first potential agent to be evaluated in humans as an Alzheimer's disease plaque modifying agent. I congratulate the Elan personnel that have made this step possible.'' Elan is a leading worldwide specialty pharmaceutical company headquartered in Ireland, with its principal research, development, manufacturing and marketing facilities located in Ireland, the United States and Israel. Elan shares trade on the New York, London and Dublin Stock Exchanges.